Latest:
Dr. Bible on Impact of Lenvatinib on Treatment Landscape of DTC
Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Keith Stewart, MD, ChB, MBA, Mayo Clinic
Latest:
Investigational Agents for Relapsed/Refractory Myeloma
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Kelin Wang, PhD
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Kelly Bailey, MD, PhD
Latest:
Dr. Bailey Discusses the Treatment of Pediatric Patients With Sarcoma
Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.
Kelly Blair
Latest:
Choosing a Care Model and Making It Work
In June, CMS selected roughly 200 medical oncology practices to participate in the public payer’s own flavor of oncology payment reform: the Oncology Care Model. This program, which launched in July, is designed to lower costs and improve quality of care for treatment episodes that start with a six-month chemotherapy regimen.
Kelly Davio
Latest:
Frontline Venetoclax/Obinutuzumab Combo Emerges as Treatment Option for CLL With CKT
Othman Al-Sawaf, MD, discusses findings from the CLL14 trial, the rationale for exploring this proposed combination, and shares his thoughts on the emerging treatment paradigms in chronic lymphocytic leukemia.
Kelly Hunt, MD
Latest:
Dr. Hunt on Treating Local Regional Recurrence in Breast Cancer
Kelly Hunt, MD, professor and chair of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with breast cancer who have local regional recurrence.